Lymphoid enhancer binding factor-1 (LEF1): as a prognostic factor in patients with Chronic lymphocytic leukemia

Document Type : Original Article

Authors

1 Clinical pathology. Faculty of medicine. Zagazig university. El sharia governorate.eygpt

2 Clinical Pathology-Faculty of Medicine Zagazig University-Egypt

3 Department of clinical pathology , faculty of medicine , Zagazig University

4 medical oncology-Faculty of Medicine Zagazig University-Egypt

Abstract

Abstract:

Background: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the world. CLL involves the abnormal activation of Wingless-type (Wnt) signaling pathway. Lymphoid enhancer-binding factor 1 (LEF1) is a member of the LEF1/T-cell factor (TCF) family of transcription factors
Aim: To evaluate LEF1 expression in CLL and its impact on risk stratification and response to therapy.
Subjects and methods: This study was conducted on 32 patients recently diagnosed as chronic lymphocytic leukemia . Complete blood picture, LDH , bone marrow aspiration , immunophenotyping , cytogenetic analysis and assessment of LEF1 expression by real time PCR were done for all patients.
Results: The prognostic value for LEF1 was evaluated. There was a significant difference between Low LEF group and high LEF group as regards mortality (P .006), All the patients in low LEF group were alive at the end of follow up period, while in high LEF group five were alive at the end of follow up period and two died during the study. The overall survival of patient's low LEF level was longer than patients with high LEF level. Such difference was statistically significant (P=0.005).
Conclusion: level of expression of LEF in CLL patients may be valuabale in predicting the survival

Keywords

Main Subjects

Zagazig University Medical Journal
Volume 29, Issue 2
March 2023
Pages 469-478

Files

Share

How to cite

Statistics